Welcome to our dedicated page for Vanda Pharmaceuticals SEC filings (Ticker: VNDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vanda Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vanda Pharmaceuticals's regulatory disclosures and financial reporting.
Vanda Pharmaceuticals reported a Form 144 stating intended sales of Common Stock totaling 30,000 shares. The filing lists planned vesting/settlement amounts of 6,602 shares on 03/15/2024, 17,307 shares on 06/08/2024, and 6,091 shares on 03/15/2025.
Vanda Pharmaceuticals reports that the FDA has approved BYSANTI (milsaperidone) tablets for adults with schizophrenia and for acute manic or mixed episodes in bipolar I disorder. The drug is an atypical antipsychotic and a new chemical entity that rapidly converts to iloperidone, showing bioequivalence across the therapeutic dosing range.
The company highlights that milsaperidone builds on extensive Fanapt (iloperidone) data, including more than 100,000 patient-years of real‑world use, offering a novel option with a familiar safety profile. It is also being studied as a once-daily adjunctive therapy in treatment‑resistant major depressive disorder, with that study expected to complete by year‑end.
Vanda anticipates commercial availability in Q3 2026 and expects marketing exclusivity supported by regulatory data protections and U.S. patents lasting to 2044. The label carries a boxed warning about increased mortality in elderly patients with dementia‑related psychosis and details multiple safety risks typical for atypical antipsychotics.
Wijkstrom Joakim reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals senior vice president and chief marketing officer Joakim Wijkstrom received an equity grant covering 125,000 shares of common stock in the form of time-based restricted stock units (RSUs). These RSUs vest in four equal annual installments starting on March 1, 2027, contingent on his continued employment through each vesting date. After this award, his directly held common stock (including RSU-related shares as reported) totals 364,269 shares. The grant was recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than an open-market purchase.
Birznieks Gunther reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals senior vice president of business development Gunther Birznieks reported an equity award in the form of 125,000 shares of common stock underlying a time-based restricted stock unit (RSU) grant. The RSUs vest in four equal annual installments, with the first vesting on March 1, 2027, as long as he remains continuously employed through each vesting date. Shares that vest will be delivered on the first permissible trading day defined in the RSU agreement. Following this grant, his directly held common stock position is 536,628 shares.
Williams Timothy reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals senior executive Timothy Williams received an equity award of 125,000 shares of common stock in the form of restricted stock units. These RSUs are scheduled to vest in four equal annual installments starting on March 1, 2027, contingent on his continued employment through each vesting date. After this grant, his directly held common stock reported in this filing totals 419,884 shares.
Vanda Pharmaceuticals Inc. reported that SVP, CFO & Treasurer Kevin Patrick Moran acquired 125,000 shares of common stock on February 18, 2026 through a time-based restricted stock unit (RSU) award granted at a price of $0.00 per share. The RSU represents common stock that will vest in four equal annual installments, with the first vesting on March 1, 2027, as long as he remains continuously employed through each vesting date. After this grant, he directly owns 453,822 shares of common stock, and there are an additional 635 shares reported as indirectly owned by his wife.
Polymeropoulos Mihael Hristos reported acquisition or exercise transactions in this Form 4 filing.
Vanda Pharmaceuticals President and CEO Mihael Hristos Polymeropoulos received an equity grant of 525,000 shares of common stock in the form of time-based restricted stock units. The award was recorded at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
The RSUs vest in four equal annual installments, with the first vesting date on March 1, 2027, as long as he remains continuously employed through each vesting date. Following this grant, his directly held common stock position is reported as 2,860,731 shares.
Vanda Pharmaceuticals detailed new pay and equity awards for its senior executives. The compensation committee granted 2025 cash bonuses, including $834,326 for CEO Mihael Polymeropoulos and amounts in the low $270,000 range for several other named officers.
For 2026, the CEO’s base salary was set at $994,625 with a target bonus of 80% of salary, while other named executives will earn base salaries of about $576,735–$596,990 with 45% bonus targets. The committee also granted substantial equity: the CEO received 525,000 RSUs and 175,000 target PSUs, and each other named officer received 125,000 RSUs and 40,000 target PSUs.
RSUs vest in four equal annual installments starting March 1, 2027. PSUs pay out between 50% and 150% of target based on relative total shareholder return versus the Nasdaq Biotechnology Index between December 31, 2025 and December 31, 2028, with any earned PSUs vesting on March 1, 2029.
Vanda Pharmaceuticals Inc. has filed a shelf registration to offer up to $200,000,000 of securities. The company may, from time to time, sell common stock, preferred stock, debt securities, warrants or units in one or more offerings, with terms set in future supplements.
The securities may be sold directly, through agents, or via underwriters, and net proceeds are intended for general corporate purposes. Vanda’s common stock trades on the Nasdaq Global Market under the symbol VNDA, with a last reported sale price of $7.43 per share on February 11, 2026.
Vanda Pharmaceuticals Inc. files its annual report outlining 2025 product sales and a broad late-stage pipeline. The company generated 2025 net sales of $117.3 million from Fanapt, $71.4 million from HETLIOZ, $27.4 million from PONVORY, and no reported U.S. sales yet for its newly approved motion sickness drug.
Vanda markets four commercial products and is advancing multiple late-stage programs, including an NDA for milsaperidone in bipolar I disorder and schizophrenia, an NDA for tradipitant in gastroparesis, and a BLA for imsidolimab in generalized pustular psoriasis. The company faces significant risks from generic HETLIOZ competition, complex FDA interactions on several indications, reliance on a few major customers, and extensive patent and regulatory litigation while pursuing global expansion and new indications.